AtriCure Receives CE-Mark for the EnCompass® Clamp
AtriCure, Inc. (ATRC)
Last atricure, inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.atricure.com
Company Research
Source: Business Wire
Approval provides new catalyst for AtriCure’s international growth MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval to sell the EnCompass® Clamp in CE-marked countries in the European Union, and European surgeons have recently performed the first series of cases with AtriCure’s EnCompass Clamp. The EnCompass Clamp received FDA 510(K) clearance and was launched in the United States in 2022.“Launching our EnCompass Clamp in Europe represents a significant expansion of our product line internationally,” said Michael Carrel, President and CEO of AtriCure. “We have seen this product have a positive impact in the United States over the last two years by advancing treatment concomitant to cardiac surgery. We are excited to offer this safe, innovative, and eff
Show less
Read more
Impact Snapshot
Event Time:
ATRC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATRC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATRC alerts
High impacting AtriCure, Inc. news events
Weekly update
A roundup of the hottest topics
ATRC
News
- AtriCure to Participate in the Piper Sandler 36th Annual Healthcare ConferenceBusiness Wire
- AtriCure to Participate in the Stifel 2024 Healthcare ConferenceBusiness Wire
- US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results [Yahoo! Finance]Yahoo! Finance
- AtriCure, Inc. (NASDAQ: ATRC) had its price target raised by analysts at Canaccord Genuity Group Inc. from $49.00 to $53.00. They now have a "buy" rating on the stock.MarketBeat
- AtriCure, Inc. (NASDAQ: ATRC) had its price target raised by analysts at Oppenheimer Holdings Inc. from $32.00 to $36.00. They now have an "outperform" rating on the stock.MarketBeat
ATRC
Earnings
- 10/29/24 - Beat
ATRC
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SCHEDULE
- 10/30/24 - Form 10-Q
- ATRC's page on the SEC website